BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31286314)

  • 1. Elevated Maximum Core Body Temperature During Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) is Associated with Increased Postoperative Complications.
    Hendrix RJ; Kassira JP; Lambert LA
    Ann Surg Oncol; 2020 Jan; 27(1):232-239. PubMed ID: 31286314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restrictive Intraoperative Fluid Therapy is Associated with Decreased Morbidity and Length of Stay Following Hyperthermic Intraperitoneal Chemoperfusion.
    Hendrix RJ; Damle A; Williams C; Harris A; Spanakis S; Lambert DH; Lambert LA
    Ann Surg Oncol; 2019 Feb; 26(2):490-496. PubMed ID: 30515670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Core Body Temperature but Not Intraabdominal Pressure Predicts Postoperative Complications Following Closed-System Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Administration.
    Goldenshluger M; Zippel D; Ben-Yaacov A; Dux J; Yalon T; Zendel A; Rayman S; Mor E; Berkenstadt H; Fogel-Grinvald H; Ventorrero M; Nissan A
    Ann Surg Oncol; 2018 Mar; 25(3):660-666. PubMed ID: 29285641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
    Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
    Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
    Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
    Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
    Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
    Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where Oncologic and Surgical Complication Scoring Systems Collide: Time for a New Consensus for CRS/HIPEC.
    Lehmann K; Eshmuminov D; Slankamenac K; Kranzbühler B; Clavien PA; Vonlanthen R; Gertsch P
    World J Surg; 2016 May; 40(5):1075-81. PubMed ID: 26669784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Tan JW; Tan GHC; Ng WY; Ong CJ; Chia CS; Soo KC; Teo MCC
    Int J Clin Oncol; 2020 May; 25(5):984-994. PubMed ID: 31915944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
    Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
    Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
    Lee L; Alie-Cusson F; Dubé P; Sideris L
    J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, Risk Factors, and Prevention Strategies for Venous Thromboembolism after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Khan S; Kelly KJ; Veerapong J; Lowy AM; Baumgartner JM
    Ann Surg Oncol; 2019 Jul; 26(7):2276-2284. PubMed ID: 31065960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.